31 results about "Cancer susceptibility" patented technology

The present invention provides methods for determining cancer susceptibility in a human subject by identifying in a nucleic acid sample from the subject, a nucleotide occurrence of a single nucleotide polymorphism (SNP) of the STK15 gene, including the STK15 Ile31 polymorphism. The invention provides isolated polynucleotides, polypeptides, specific binding pair members, and cells useful for identifying agents that affect tumor susceptibility. Furthermore, the invention provides methods for detecting low penetrance tumor susceptibility genes.

Heparinized human whole blood from patients with invasive breast cancer, with (multiple primary) and without (single primary) a second primary cancer, and from unaffected controls was stimulated with 0.1-10 Gy of radiation and incubated at 37° C. for 2 hours. P21 and PUMA mRNA were then quantified. The results suggest that cancer susceptibility represented by the multiple primary cases was significantly related to over-reaction of p21 mRNA, and not PUMA.

The invention provides a primer for detecting a rectal-cancer-susceptibility-related SNP site .The primer includes a C11orf93 gene rs3802842 site primer, an SMAD7 gene rs4939827 site primer, a POU5F1B gene rs6983267 site primer and an RNA5SP229 gene rs10795668 site primer .A method for detecting the rectal-cancer-susceptibility-related SNP site with the primer includes the following steps that 1, samples are collected, and DNA is extracted; 2, target genes are subjected to PCR amplification and gel recovery through the four primers respectively; 3, the gel recovery products are subjected to concentration measurement and PCR amplification and purified; 4, the purified products are subjected to sample loading, and the SNP detecting results are analyzed .The primer is good in specificity, high in sensitivity and good in accuracy, the detection method is simple, and the rectal-cancer suffering risk of a detected patient can be forecasted.

A region on chromosome 8q24.21 has been demonstrated to play a major role in particular forms of cancer. It has been discovered that certain markers and haplotypes are indicative of a susceptibility to particular cancers, including prostate cancer. Diagnostic applications for identifying a susceptibilty to cancer using these markers and haplotypes are described.

A method for the early diagnosis, prognosis or clinical monitoring of cancer disease based on the quantitation of DNA in a plasma sample from a cancer patient, a subject with cancer susceptibility or an individual at risk of developing cancer.

The present invention relates to a rectal adenocarcinoma susceptibility prediction kit, which comprises the following components: STR-1 primer, STR-2 primer, STR-3 primer, STR-4 primer, STR-5 primer, STR-6 primer; Further, it may also include: PCR amplification reaction solution, LIZ-500 molecular weight internal standard, deionized formamide. The rectal adenocarcinoma susceptibility prediction kit of the present invention can be used for the diagnosis and susceptibility prediction of rectal adenocarcinoma. The invention also provides a rectal adenocarcinoma susceptibility prediction system.

The invention relates to a PCR primer and application of the coding sequences of human breast cancer susceptibility genes BRCA1 and BRCA2 based on NGS technology. The PCR primers of the human breast cancer susceptibility genes BRCA1 and BRCA2 coding sequences include at least one pair of capture primers, and the sequences of the forward primer and reverse primer of each pair of capture primers include specific sequences and are compatible with the described Linker sequence to which the 5' end of the specific sequence is ligated. The PCR primers and applications for amplifying the coding sequences of human breast cancer susceptibility genes BRCA1 and BRCA2 based on NGS technology, the experimental operation involved in the whole method is simple, only involves PCR reagents and primer combinations, the cost is low, and double tags are introduced at the same time Sequence adapter sequence is used to distinguish different samples, which can realize high-throughput sample sequencing detection, and can effectively provide genetic detection support for risk assessment of human breast cancer and other BRCA susceptibility genes-related hereditary tumors or targeted drugs for BRCA mutations .

Methods and compositions for the diagnosis of cancer susceptibilities, defective DNA repair mechanisms and treatments thereof are provided. Among sequences provided here, the FANCD2 gene has been identified, and probes and primers are provided for screening patients in genetic-based tests and for diagnosing Fanconi Anemia and cancer. The FANCD2 gene can be targeted in vivo for preparing experimental mouse models for use in screening new therapeutic agents for treating conditions involving defective DNA repair. The FANCD2 polypeptide has been sequenced and has been shown to exist in two isoforms identified as FANCD2-S and the monoubiquinated FANCD-L form. Antibodies including polyclonal and monoclonal antibodies have been prepared that distinguish the two isoforms and have been used in diagnostic tests to determine whether a subject has an intact Fanconi Anemia / BRCA pathway.

The lifetime probability of a person developing cancer can now be determined based on an allelic variation found in the 3′UTR of the prohibitin gene. The probability is dependent on the sequence of the 3′UTR at position 729, i.e., whether there is a thymine (T) or a cytosine (C) or both at this position. Determining the sequence at the position 729 can be done by any number of standard techniques. Preferably, the sequence is determined by amplifying this region by PCR and subjecting it to an RFLP analysis.

The present disclosure provides methods for estimating cancer susceptibility, risk of developing multiple tumor sites, and the aggressiveness of prostate cancer. Disclosed are interactions among three polymorphisms: the Acid Phosphatase Locus-1 (ACP1) 228C>T (rs11553742) and 413A>G (Q106R, rs79716074) single nucleotide polymorphisms (SNPs), and a SNP for the Astrocyte Elevated Gene-1 (AEG1) (rs2438211). Additionally interactions among these polymorphisms are disclosed to modify the underlying quantitative expression of major cancer-related genes, indicating that optimization of these gene products by pharmacologic or gene therapy interventions would be beneficial as a cancer therapy to reduce the risk of tumor metastasis, and would also be beneficial in preventing cancer.

Described herein are genetic pharmacopoeia for querying for individual cancer susceptibility to available molecular targeted therapies.

The invention relates to a method for forecasting the onset age of colon cancer and a kit, which pertains to the medical biotechnology and the genetic diagnosis field. The method for forecasting colon cancer susceptibility determines the genotype of C53 gene polymorphism 1808 site (rs2737) of a subject and forecasts the colon cancer susceptibility of the subject by extracting the host cell genomeDNA. The method has the advantages that: the relevance of the C53 gene polymorphism site with the onset age of colon cancer is firstly expounded, the method for forecasting colon cancer susceptibility is provided, and the method can be used for the prevention, the auxiliary diagnosis and treatment of colon cancer, as well as the development of new drugs.